Buspirone augmentation of fluoxetine in obsessive-compulsive disorder
- 1 June 1990
- journal article
- research article
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 147 (6) , 798-800
- https://doi.org/10.1176/ajp.147.6.798
Abstract
Eleven obsessive-compulsive patients underwent a prospective open-label trial of fluoxetine monotherapy followed by buspirone augmentation. The combination therapy was statistically superior to fluoxetine monotherapy. The results point to the importance of the 5-HT1.alpha. receptor in obsessive-compulsive disorder.This publication has 9 references indexed in Scilit:
- Open trial of fluoxetine in obsessive-compulsive disorderAmerican Journal of Psychiatry, 1989
- Fluoxetine in the Long-Term Maintenance Treatment of Obsessive Compulsive DisorderPsychiatric Annals, 1989
- Efficacy of Fluvoxamine in Obsessive-Compulsive DisorderArchives of General Psychiatry, 1989
- Drs. Jenike and Baer ReplyAmerican Journal of Psychiatry, 1988
- 5-Hydroxytryptamine Receptor SubtypesAnnual Review of Neuroscience, 1988
- Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiologyBiological Psychiatry, 1987
- An Open Clinical Trial of Fluoxetine in the Treatment of Obsessive-Compulsive DisorderJournal of Clinical Psychopharmacology, 1986
- Modulation of serotonin release in the brain via presynaptic receptorsTrends in Pharmacological Sciences, 1982
- Clomipramine Treatment of Obsessive-Compulsive DisorderArchives of General Psychiatry, 1980